Abstract
In vitro drug combination studies are commonly used for CLL primary lymphocytes. An advancement in this method is to perform ex vivo drug testing where the first agent is administered to patients and second drug is tested in these patients’ cells in vitro. These assays have been effective in identifying novel agents that work additively or synergistically. In this chapter, we provide a step-by-step protocol for ex vivo drug testing that can be used for combination strategies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ponader S, Burger JA (2014) Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol 32(17):1830–1839
Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, Gandhi V (2017) Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res 23(14):3734–3743
Yang Q, Modi P, Ramanathan S, Quéva C, Gandhi V (2015) Idelalisib for the treatment of B-cell malignancies. Expert Opin Orphan Drugs 3(1):109–123
Vangapandu HV, Jain N, Gandhi V (2017) Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26(5):625–632
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311–322
Bose P, Gandhi V (2017) Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res 6:1924
Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V (2015) Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 21(16):3705–3715
Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V (2015) Proteasome inhibitor carfilzomib complements ibrutinib’s action in chronic lymphocytic leukemia. Blood 125(2):407–410
Patel V, Lamothe B, Ayres M, Gay J, Cheung J, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating M (2017) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32(4)
Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG (2017) Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia 31(9):1872
Acknowledgments
Authors thank CLL Global Research Foundation Alliance grant and MD Anderson Cancer Center CLL Moon Shot Award.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Aslan, B., Ayres, M.L., Gandhi, V. (2019). Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells. In: Malek, S. (eds) Chronic Lymphocytic Leukemia. Methods in Molecular Biology, vol 1881. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8876-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8876-1_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8875-4
Online ISBN: 978-1-4939-8876-1
eBook Packages: Springer Protocols